Table 2.
Multivariable Analysis.
| Variable | 1° Model | 2° Model | 3° Model | 4° Model | ||||
|---|---|---|---|---|---|---|---|---|
| HR (95% CI) | p≤ | HR (95% CI) | p≤ | HR (95% CI) | p≤ | HR (95% CI) | p≤ | |
| PSA (ng/mL) | ||||||||
| <35 ng/mL | 1 | 1 | 1 | 1 | ||||
| ≥35 ng/mL | 6.63 (0.52–84.11) | 0.1 | 7.31 (0.54–98.24) | 0.1 | 6.47 (0.49–85.59) | 0.1 | 5.47 (0.38–78.17) | 0.2 |
| Treatment line * | ||||||||
| 1L | 1 | 1 | 1 | 1 | ||||
| >2L | 2.54 (0.53–12.08) | 0.2 | 4.03 (0.95–17.14) | 0.06 | 3.17 (0.70–14.35) | 0.1 | 2.21 (0.44–11.19) | 0.3 |
| Metastatic sites | ||||||||
| =1 site | 1 | 1 | 1 | 1 | ||||
| >1 sites | 1.56 (0.36–6.93) | 0.5 | 1.66 (0.38–7.21) | 0.5 | 1.93 (0.45–8.33) | 0.4 | 2.15 (0.39–12.20) | 0.4 |
| AR-V7 | ||||||||
| Negative | 1 | 1 | ||||||
| Positive | 6.09 (1.53–24.31) | 0.01 | − | − | − | − | 8.96 (0.94–85.38) | 0.057 |
| CTC | ||||||||
| Negative | 1 | 1 | ||||||
| Positive | − | − | 2.85 (0.42–19.18) | 0.3 | − | − | 1.08 (0.07–16.94) | 0.9 |
| AR-FL | ||||||||
| Negative | 1 | 0.2 | 1 | 0.6 | ||||
| <10 copies/mL | − | − | − | − | 2.80 (0.48–16.36) | 0.2 | 1.91 (0.15–23.76) | 0.6 |
| ≥10 copies/mL | 4.16 (0.83–20.89) | 0.08 | 0.73 (0.04–14.33) | 0.8 | ||||
| C-Index | 0.92 (0.86–0.98) | 0.86 (0.77–0.94) | 0.87 (0.78–0.95) | 0.91 (0.85–0.98) | ||||
* 1L = first-line therapy for metastatic castration-resistant prostate cancer (mCRPC); >2L = third-line or more for mCRPC.